Jobs
View more job listings or post a job
Hangzhou Zenshine Pharmaceuticals Director/Senior Director, Oncology
Genentech Scientific Researcher / Senior Scientific Researcher, Drug Metabolism And Pharmacokinetics
Hughes and Associates Senior Scientist Large Molecule Bioanalysis
Hughes and Associates Associate Director DMPK
Hughes and Associates Associate Director, Clinical Pharmacology and Pharmacometrics
Hughes and Associates Senior Director Clinical Pharmacology
Genentech ASSOCIATE SCIENTIST/SCIENTIST – DRUG METABOLISM
Genentech Scientist–Drug Metabolism (Contract 2)
Genentech Scientist–Drug Metabolism (Contract 1)  
Drug Delivery Experts Associate Scientist
Post a job

Seminar luncheon

Convertible CAR-T cells with a steering wheel, accelerator, and brake for cancer therapy


Speakers: David W. Martin, MD, Chairman and Chief Scientific Officer, Xyphos Bioscience
Organizers: Shichang Miao, PhD
Date: 12/14/2018
Time: 11:00-14:00
Registration fee (USD): ;
Location: SF Bay Area: Foster City Crowne Plaza
Major Sponsor:
Vendor show vendors registered to date: (4)BioTechne (R&D Systems); DyChrom; Novogene Corporation; PHC former Panasonic Healthcare
Registration: http://www.PBSS.org
Registration deadline:12/11/2018  (it will close sooner if the seating cap is reached)

About the Topic

The recent progress in the field of immuno-oncology has dramatically changed the clinical approach to treating cancer. Tremendous excitement centers on Adoptive Cell Therapy (ACT), an approach that delivers living cells derived from the human immune system and engineered to target and kill cancer cells. Results from numerous clinical studies of pioneer CAR-T therapy products showed tremendous success and provided evidence of complete and durable cancer remissions. However, at the same time, many challenges to effect safe and effective CAR-T therapy became evident.

Building on the success of the pioneer CAR-T therapies, Xyphos is developing best-in-class CAR-T therapy products based on our ACCEL technology which includes our universal 
convertible
CAR and a family of bispecific, antibody-like adaptor molecules, called MicAbodies™ and MicAdaptors. Our vision is to provide precision, control, safety and ultimately durable efficacy to this revolutionary class of cancer therapy. Further details are at https://xyphosinc.com/strategy/.


About the Speakers

DAVID W. MARTIN, MD, Chairman and Chief Scientific Officer

Dr. Martin is a Co-founder of Xyphos. He has previously held executive and scientific leadership roles in biotechnology and pharmaceutical companies including SVP of R&D at Genentech (1982-1990); Executive VP of R&D at DuPont Merck (1991-1993); President of Chiron Therapeutics (1994-1995); and Founder and CEO of Eos Biotechnology (1997-2003); and Co-founder and CEO of AvidBiotics (2004-2017). Additionally, he has served as Director and Lead Director of Cubist Pharmaceuticals and Varian Medical Systems, each for more than a decade. Dr. Martin trained at Duke Medical School, was Professor of Medicine and Biochemistry at University of California, San Francisco, and Investigator of the Howard Hughes Medical Institute. He is currently a member of the Oversight Committee for the California Institute for Regenerative Medicine.


2019-01-18, Fluorescence Imaging for the da Vinci Robotic Surgery Platform
2019-02-07, Covalent Inhibitor Drug Discovery & Development: Biology, Chemistry, PK, Safety and Case Studies (Jointly with Bay Area PKPD Network)
2019-03-07, Promising therapeutic approaches and transnational medicine from SPARK: an academic-industry collaboration to advance novel therapeutics (A Joint Symposium by PBSS and Stanford SPARK Program)
2019-03-11, Clinical Trials Essentials: An Intensive One-Week Course (register for the full week or half day sessions)
┬ęPharmaceutical & BioScience Society, International; Last Modified: 12/18/2018; Visited: 459; Admin Logon
Ads (in random order)
Submit a Text Ad
($200 for 2 months)